Chagas disease is an intestinal worm infection caused by the T. cruiselius fungus. Chagas is a very common disease that is most commonly transmitted through unguarded shared food or water containers. Most cases occur in poor communities where basic health care is lacking, which means that the disease cannot be detected and treated in a timely manner. Chagas infection is associated with numerous mild to severe complications. Common complications associated with Chagas infection include diarrhea, dehydration, shock, kidney failure, heart failure, and death. Some cases of chagas can be fatal and even result in necrosis of the affected organs. For chagas with no apparent medical cause, the primary means of treatment is prevention through proper hygiene. In the past year, Chagas disease has spread to developed economies such as Europe and North America due to the migration of people from Latin America to other countries. For example, in 2015, 4.2% of Latin Americans living in European countries were chronically affected by Chagas disease, according to a study published in the National Center for Biotechnology Information (NCBI). Benznidazole is the only FDA-approved drug for the treatment of Chagas disease. The drug Nifurtimox manufactured by Bayer AG is on the list of “Essential Medicines” of the World Health Organization (WHO) and is used to treat Chagas disease. Get Sample Report With Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/934 The Launch of a New Chagas Disease Treatment Chagas Disease Drug Market is Expected to Grow the Global Treatment of the Boosting Chagas Disease Benznidazole is an important anti-parasitic drug that is widely used to treat Chagas Disease. In April 2018, for example, the Argentine National Authority for Drugs, Food and Medical Technology (ANMAT) approved the drug benznidazole from Laboratorio Elea Phoenix SA for the pediatric indication for the treatment of Chagas disease. Currently, Argentina has the largest number of people with Chagas disease. According to data released by Mundo Sano (non-governmental foundation in Argentina), around 7,300,000 people were exposed to Chagas disease and around 1,600,000 became infected in Argentina in 2017. Hence, increasing approval of new drugs is expected to increase market growth in the near future. This approval of drugs for the treatment of Chagas disease is expected to fuel the growth of the Chagas disease treatment market in the near future. The global Chagas treatment disease market was estimated at $ 5.67 million in 2016 and is expected to have a CAGR of 7.3% over the forecast period (2017-2025). Increasing initiatives by private and government organizations to raise awareness of Chagas disease In April 2018, Médecins Sans Frontières / Doctors Without Borders (MSF), an international humanitarian organization, launched a campaign. The campaign aims to raise public awareness of Chagas disease as the disease is still widespread in Latin American countries and affects approximately 6 million people worldwide. In 2007 the World Health Organization (WHO) started a program to increase the treatment rate and eradicate Chagas disease. This WHO program was supported by Bayer HealthCare, a manufacturer of nifurtimox, which is used to treat Chagas disease. In 2007 Bayer signed an agreement with the WHO to support the program by providing 2.5 million tablets free of charge to the WHO for the treatment of an estimated 30,000 patients over a period of five years (from 2007 to 2011). In 2011 the WHO and Bayer extended their agreement. According to the agreement, Bayer is expected to provide 5 million tablets free of charge between 2012 and 2017. Such initiatives are intended to drive market growth in the near future Download PDF Brochure with Latest Insights @ https: //www.coherentmarketinsights .com / insight / request-pdf / 934 Diagnostic Methods Diagnosis of Chagas disease is mainly done through blood tests and microscopic examination of body fluids . This disease is caused by parasites that live in the feces and can be transmitted to other parts of the body through blood, secretions, and bite marks. The first step in Chagas diagnosis is drawing fresh blood samples to obtain serum samples. Serum samples are then sent to a laboratory for testing. It is mainly carried out by serological methods, parasitological methods, and molecular methods. Parasitological methods include the identification of trypomastigotes in the blood by microscopy. The polymerase chain reaction (PCR) is a widely used molecular diagnostic method because it is an ideal alternative tool for detection and is highly efficient. The serological method is mainly used for the detection of Trypanosoma cruzi antibodies in blood donors, for diagnosing infected people and for epidemic studies. Enzyme-linked Immunosorbent Assay (ELISA), Indirect Immunofluorescence (IIF) are the most widely used tests in the serological method. The availability of rapid diagnostic and point-of-care methods has made diagnosing the disease easier and faster. In 2016 InBios International, Inc. received 510K approval from the US Food and Drug Administration (FDA) for its Chagas Detect Plus Rapid Test Kit (CDP). Major players in the Chagas disease treatment market include Nortec Quimica SA, Bayer AG, Laboratorio Elea Phoenix SA, Maprimed SA, and Laboratório Farmacêutico de Pernambuco S / A. Buy This Premium Report for Access Complete Information: https://www.coherentmarketinsights.com/insight/buy-now/934 Table of Contents Global Chagas Disease Treatment Market Research Report Section 1: Global Chagas Disease Treatment Industry Overview Section 2: Global Economic Impact On Chagas Disease Treatment Industry Section 3: Global Market Competition From Industrial Manufacturers Section 4: Global Productions, Revenue (Value), By Regions Section 5: Global Deliveries (Production), Consumption, Export, Import, Geographical Section 6: Global Productions, Revenue (Value), Price Trend, Product Type Section 7: Global Application Based Market Analysis Section 8: Market Price Analysis For Chagas Disease Treatment Section 9: Market Chain, Sourcing Strategy And Downstream Buyers Section 10: Strategies And Key Policies Of Distributors / Suppliers / Dealers Section 11: Key Marketing St Section 12: Market Effect Factors Analysis Section 13: Global Chagas Disease Tr Nutrition Market Forecast More Reports Bacteriophage Therapy Market Brain Computer Interfaces Market About Us: Coherent Market Insights is a global research and advisory firm that provides syndicated research reports, bespoke research reports and Provides advisory services. We’re known for our actionable insights and authentic reports in a variety of fields including Aerospace & Defense, Agriculture, Food and Beverage, Automotive, Chemistry and Materials, and virtually every field and comprehensive list of sub-fields under the sun. We create value for our customers through our extremely reliable and accurate reports. We also strive to play a leading role in providing insights into various sectors following COVID-19 and continue to deliver measurable, sustainable results for our customers. Contact: Coherent Market Insights 1001 4th Ave, # 3200 Seattle, WA 98154, USEmail: sales@coherentmarketinsights.com United States: + 1-206-701-6702 United Kingdom: + 44-020-8133-4027 Japan: + 050-5539-1737 India : + 91-848-285-0837
[ad_2]
